Patents by Inventor Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANDROGEN RECEPTOR BY DOUBLE-STRANDED RNA
    Publication number: 20130131149
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing AR target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 23, 2013
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventor: Dicerna Pharmaceuticals, Inc.
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA
    Publication number: 20130123342
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
    Type: Application
    Filed: January 10, 2013
    Publication date: May 16, 2013
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventor: Dicerna Pharmaceuticals, Inc.
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA
    Publication number: 20130109740
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: December 18, 2012
    Publication date: May 2, 2013
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventor: Dicerna Pharmaceuticals, Inc.
  • SINGLE STRANDED EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION
    Publication number: 20130096290
    Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
    Type: Application
    Filed: December 7, 2012
    Publication date: April 18, 2013
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventor: Dicerna Pharmaceuticals, Inc.